TimeScale Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

TimeScale Financial’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$448	Hold	125	–	–	﹤0.01%	579
2023 Q1	$273	Hold	125	–	–	﹤0.01%	587
2022 Q4	$810	Hold	125	–	–	﹤0.01%	516
2022 Q3	$1K	Hold	125	–	–	﹤0.01%	513
2022 Q2	$1K	Hold	125	–	–	﹤0.01%	484
2022 Q1	$1K	Hold	125	–	–	﹤0.01%	500
2021 Q4	$2K	Hold	125	–	–	﹤0.01%	449
2021 Q3	$3K	Hold	125	–	–	﹤0.01%	416
2021 Q2	$2K	Hold	125	–	–	﹤0.01%	441
2021 Q1	$1K	Hold	125	–	–	﹤0.01%	480
2020 Q4	$1K	Hold	125	–	–	﹤0.01%	407
2020 Q3	$0	Buy	125 +41	+49%	+$143	﹤0.01%	496
2020 Q2	$0	Buy	+84	New	+$282	﹤0.01%	469

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TimeScale Financial's ORMP Position: Q2 2023 in Review

TimeScale Financial held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2023 at 125 shares worth $448. The position accounts for ﹤0.01% of the portfolio, ranked #579.

TimeScale Financial first reported a position in ORMP in Q2 2020 and has held it in 13 quarters since. The position peaked at $3K in Q3 2021. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

TimeScale Financial held 125 shares of Oramed Pharmaceuticals worth $448 as of Q2 2023.
TimeScale Financial left its Oramed Pharmaceuticals share count unchanged in Q2 2023.
Oramed Pharmaceuticals made up ﹤0.01% of TimeScale Financial's portfolio in Q2 2023, its #579 holding.
TimeScale Financial first reported a position in Oramed Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
TimeScale Financial's Oramed Pharmaceuticals position peaked at $3K in Q3 2021.
50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.